Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
Conditions
- B-cell Chronic Lymphocytic Leukemia
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Splenic Marginal Zone Lymphoma
- Waldenström Macroglobulinemia
Interventions
- BIOLOGICAL: therapeutic autologous lymphocytes
- DRUG: cyclophosphamide
- BIOLOGICAL: aldesleukin
- GENETIC: polymerase chain reaction
- GENETIC: gene rearrangement analysis
- PROCEDURE: lymph node biopsy
- BIOLOGICAL: genetically engineered lymphocyte therapy
- PROCEDURE: bone marrow aspiration
- OTHER: flow cytometry
- OTHER: laboratory biomarker analysis
- OTHER: enzyme-linked immunosorbent assay
Sponsor
Fred Hutchinson Cancer Center
Collaborators